VYNE Therapeutics Inc.
VYNE
$0.59
$0.000.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.84M | -7.28M | -5.76M | -8.61M | -12.02M |
| Total Depreciation and Amortization | 5.00K | 6.00K | 6.00K | 6.00K | 4.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 439.00K | 337.00K | 315.00K | 439.00K | 154.00K |
| Change in Net Operating Assets | 629.00K | -159.00K | -5.37M | -3.30M | 2.87M |
| Cash from Operations | -3.76M | -7.10M | -10.80M | -11.46M | -9.00M |
| Capital Expenditure | -- | -- | -- | -- | -117.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.46M | 4.40M | 4.68M | 19.83M | 12.86M |
| Cash from Investing | 8.46M | 4.40M | 4.68M | 19.83M | 12.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -15.00K | -7.00K | -34.00K | -87.00K | -132.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.00K | -7.00K | -34.00K | -87.00K | -132.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.68M | -2.70M | -6.16M | 8.28M | 3.61M |